Atricure News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Atricure. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Atricure Today - Breaking & Trending Today

AtriCure (NASDAQ:ATRC) PT Lowered to $40.00

AtriCure (NASDAQ:ATRC – Free Report) had its target price trimmed by Needham & Company LLC from $46.00 to $40.00 in a research report report published on Thursday morning, Benzinga reports. The brokerage currently has a buy rating on the medical device company’s stock. Several other brokerages also recently commented on ATRC. StockNews.com downgraded shares of […] ....

United States , Karls Dahlquist , Stifel Nicolaus , Atricure Company Profile , Victory Capital Management Inc , Securities Exchange Commission , Riverpark Advisors , Needham Company , Atricure Inc , Allspring Global Investments Holdings , Quest Partners , Virtu Financial , Free Report , Moderate Buy , Cure Trading Down , Get Free Report , Exchange Commission , Park Advisors , Global Investments Holdings , Victory Capital Management , Capital Management , Isolator Synergy Clamps , Atricure Daily , Nasdaq Atrc , Lower Price Target , Needham Company Llc ,

AtriCure (NASDAQ:ATRC) Posts Earnings Results, Misses Estimates By $0.02 EPS

AtriCure (NASDAQ:ATRC – Get Free Report) released its earnings results on Wednesday. The medical device company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by ($0.02), Briefing.com reports. AtriCure had a negative net margin of 8.98% and a negative return on equity of 7.82%. The firm had revenue […] ....

United States , Stifel Nicolaus , Karls Dahlquist , Justinj Noznesky , Canaccord Genuity Group , Atricure Inc , Atricure Company Profile , Securities Exchange Commission , Needham Company , Get Free Report , Genuity Group , Exchange Commission , Isolator Synergy Clamps , Atricure Daily , Nasdaq Atrc ,

AtriCure (NASDAQ:ATRC) PT Lowered to $40.00 at Needham & Company LLC

AtriCure (NASDAQ:ATRC – Get Free Report) had its price objective dropped by analysts at Needham & Company LLC from $46.00 to $40.00 in a report released on Thursday, Benzinga reports. The firm currently has a “buy” rating on the medical device company’s stock. Needham & Company LLC’s price objective points to a potential upside of […] ....

United States , Karls Dahlquist , Zurcher Kantonalbank Zurich Cantonalbank , Stifel Nicolaus , Securities Exchange Commission , Needham Company , Atricure Inc , Mirae Asset Global Investments Co , Sg Americas Securities , Atricure Company Profile , Assetmark Inc , Get Free Report , Cure Stock Down , Exchange Commission , Kantonalbank Zurich Cantonalbank , Asset Global Investments , Isolator Synergy Clamps , Atricure Daily , Nasdaq Atrc , Lower Price Target , Needham Company Llc ,

AtriCure (NASDAQ:ATRC) Price Target Cut to $49.00

AtriCure (NASDAQ:ATRC – Get Free Report) had its target price cut by Canaccord Genuity Group from $57.00 to $49.00 in a report released on Thursday, Benzinga reports. The brokerage currently has a “buy” rating on the medical device company’s stock. Canaccord Genuity Group’s price target would indicate a potential upside of 134.56% from the stock’s […] ....

United States , Justinj Noznesky , Karls Dahlquist , Stifel Nicolaus , Riverpark Advisors , Virtu Financial , Atricure Inc , Securities Exchange Commission , Allspring Global Investments Holdings , Canaccord Genuity Group , Quest Partners , Victory Capital Management Inc , Atricure Company Profile , Needham Company , Get Free Report , Genuity Group , Exchange Commission , Park Advisors , Global Investments Holdings , Victory Capital Management , Capital Management , Isolator Synergy Clamps , Atricure Daily , Nasdaq Atrc , Lower Price Target , Canaccord Genuity Group Inc ,

AtriCure (NASDAQ:ATRC) Price Target Cut to $34.00

AtriCure (NASDAQ:ATRC – Get Free Report) had its price target decreased by research analysts at JPMorgan Chase & Co. from $42.00 to $34.00 in a research note issued on Thursday, Benzinga reports. The firm currently has an “overweight” rating on the medical device company’s stock. JPMorgan Chase & Co.‘s price target would indicate a potential […] ....

United States , Stifel Nicolaus , Zurcher Kantonalbank Zurich Cantonalbank , Karls Dahlquist , Justinj Noznesky , Atricure Inc , Needham Company , Jpmorgan Chase Co , Atricure Company Profile , Assetmark Inc , Mirae Asset Global Investments Co , Sg Americas Securities , Get Free Report , Kantonalbank Zurich Cantonalbank , Asset Global Investments , Isolator Synergy Clamps , Atricure Daily , Nasdaq Atrc , Lower Price Target , Jpmorgan Chase Co ,